Novocure (NSDQ:NVCR) and US Oncology Research said today that the groups are collaborating on a phase III pivotal trial designed to test Novocure’s Tumor Treating Fields with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic cancer.
Using a network of community-based oncology practices, US Oncology Research plans to open 10 clinical trial sites to enroll patients in Novocure’s Panova-3 trial, the companies reported.
Get the full story at our sister site, Drug Delivery Business News.
The post Novocure inks collaboration for pivotal pancreatic cancer trial appeared first on MassDevice.
from MassDevice https://ift.tt/2nFrj4V
Cap comentari:
Publica un comentari a l'entrada